60% højere, og AUC for rivastigmin var mere end dobbelt så høj hos personer med mildt til moderat nedsat leverfunktion end hos raske personer.
After oral administration, the Cmax of rivastigmine was approximately 60% higher and the AUC of rivastigmine was more than twice as high in subjects with mild to moderate hepatic impairment than in healthy subjects.